Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2008/2009

NCT00735410 | Completed Phase 3

• 2 other identifiers: V44P12S2008-000887-18
• Study Type: interventional
• Target: 134
• Locations: 1 country
• Sites: 1

Brief Summary

Annual trial for registration influenza vaccine with the strain composition for season 2008/2009

Conditions

Seasonal Influenza, Vaccine

Keywords

Influenza vaccine; Seasonal; Split

Outcome Measures

Primary Outcomes (1)

• Evaluation of antibody response to each influenza vaccine antigen, as measured by haemagglutination inhibition (HI) test on Day 0 and on Day 21

  21 days (-1/+7)

Secondary Outcomes (1)

• Evaluation of safety of the influenza vaccine

  21 days (-1/+7)

Study Arms (1)

1

EXPERIMENTAL

Biological: Seasonal Influenza Vaccine

Interventions

Seasonal Influenza Vaccine BIOLOGICAL

1 dose of Split influenza vaccine

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry
• available for all the visits scheduled in the study and able to comply with all study requirements
• in good health as determined by: medical history physical examination clinical judgment of the investigator

You may not qualify if:

• They Have any serious (in the judgment of the investigator) disease, including but not limited to:
• Cancer, except for localized skin cancer Advanced congestive heart failure Chronic obstructive pulmonary disease (COPD) Autoimmune disease (including rheumatoid arthritis) Acute or progressive hepatic disease Acute or progressive renal disease Severe neurological or psychiatric disorder Severe Asthma
• They have a history of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g., to ovalbumin, chicken protein, chicken feathers, influenza viral protein neomycin or polymyxin).
• Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting for example from:
• receipt of immunosuppressive therapy (any parental or oral cortical steroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study; Receipt of immunostimulants, Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months and for the full length of the study, Suspected or known HIV infection or HIV-related disease.
• Known or suspected history of drug or alcohol abuse.
• They have a bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject;
• Women who are pregnant or woman of childbearing potential unwilling to practice acceptable contraception for the duration of the study (21 days).
• Influenza vaccination or laboratory confirmed influenza within the last 6 months and more than one influenza vaccination within the past 12 months
• Within the past 4 weeks they have received:
• another vaccine any investigational agent;
• Any acute or chronic infection requiring systemic antibiotic treatment or antiviral therapy within the last 7 days.
• They have experienced fever (i.e., axillary temperature ≥ 38°C) within the last 3 days
• Simultaneous participation in another clinical study.
• Any condition, which, in the opinion of the investigator, might prevent the subject from participation or interfere with the evaluation of the study objectives.

Sponsors & Collaborators

• Novartis Vaccines: lead

Study Sites (1)

Site 1, 2 and 3

Hessen, 35033, Germany

Location

MeSH Terms

Conditions

Influenza, Human

Condition Hierarchy (Ancestors)

Respiratory Tract Infections; Infections; Orthomyxoviridae Infections; RNA Virus Infections; Virus Diseases; Respiratory Tract Diseases

Study Officials

• Novartis Vaccines

  Novartis Vaccines

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 13, 2008
• First Posted: August 15, 2008
• Study Start: June 1, 2008
• Primary Completion: July 1, 2008
• Study Completion: July 1, 2008
• Last Updated: December 1, 2016

Record last verified: 2011-11

Locations

DE (1)